Twitter

Posts Tagged ‘vemurafenib’


Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma

Vemurafenib-resistant tumors in patients with melanoma showed reduced growth after cessation of treatment, and in animal models, drug resistance was prevented by intermittent treatment, according to new data.

Read More...

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Condition :   Malignant Melanoma Interventions :   Drug: vemurafenib;   Drug: Placebo;   Drug: GDC-0973 Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified September 2012

Read More...

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Condition :   Metastatic Melanoma Intervention :   Drug: vemurafenib + HD IL-2 Sponsors :   Prometheus Laboratories;   Prometheus Laboratories Active, not recruiting – verified September 2012

Read More...

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Condition :   Melanoma Interventions :   Drug: Ipilimumab;   Biological: Vemurafenib Sponsors :   Bristol-Myers Squibb;   Bristol-Myers Squibb Not yet recruiting – verified August 2012

Read More...

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Condition :   Neoplasm Malignant- Interventions :   Drug: SAR260301;   Drug: Vemurafenib Sponsors :   Sanofi-Aventis;   Sanofi-Aventis Recruiting – verified August 2012

Read More...

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Condition :   Malignant Melanoma Interventions :   Drug: vemurafenib;   Drug: Placebo Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified August 2012

Read More...

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Condition :   Melanoma Interventions :   Drug: XL888;   Drug: Vemurafenib Sponsors :   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Exelixis Recruiting – verified August 2012

Read More...

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Condition :   Malignant Melanoma Interventions :   Drug: MPDL3280A;   Drug: Vemurafenib (Zelboraf®) Sponsors :   Genentech;   Genentech Not yet recruiting – verified August 2012

Read More...

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Conditions :   Cancer;   Advanced Solid Tumors Interventions :   Drug: Sunitinib;   Drug: Sorafenib;   Drug: Erlotinib;   Drug: Everolimus;   Drug: Lapatinib;   Drug: Dasatinib;   Drug: Pazopanib;   Drug: Vemurafenib;   Procedure: tumor biopsy;   Procedure: skin biopsy (optional) Sponsors :   VU University Medical Center;   VU University Medical Center Recruiting – verified July 2012

Read More...

Study of Vemurafenib, Carboplatin, and Paclitaxel

Condition :   Advanced Cancers Interventions :   Drug: Vemurafenib;   Drug: Carboplatin;   Drug: Paclitaxel Sponsors :   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center Not yet recruiting – verified July 2012

Read More...